CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO® The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...

SPEVIGO® approved for expanded indications in China and the US Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...

Gulf Pacific Power, LLC Acquires Peaking Facility Near Sandersville BIRMINGHAM, Ala., July 29, 2021 (GLOBE NEWSWIRE) -- Gulf Pacific Power (“GPP”), through its subsidiary Georgia Gulf Power Holdings, LLC has completed the acquisition of a 50% stake in AL...

Gulf Pacific Power Acquires Majority Stake in Wind Portfolio BIRMINGHAM, Ala., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) is pleased to announce that Gulf Pacific Power, LLC (“GPP”) has completed the acquisition of an 80% stake...